[ Price : $8.95]
FDA warns Chinas Hangzhou Yiqi Biotechnology Co. about CGMP deviations in its manufacturing of active pharmaceutical ingredients.[ Price : $8.95]
FDA publishes frequently asked questions covering eligibility, statement of interest, and selection of participants for the TEMPO ...[ Price : $8.95]
FDA warns Chinas Harbin Jixianglong Biotech about CGMP deviations and other violations in its manufacturing of active pharmaceutic...[ Price : $8.95]
A Stanford Law School Center for the Law and Biosciences fellow says policymakers should consider the growth in breakthrough medic...[ Price : $8.95]
FDA grants Bayer a priority review for its NDA for asundexian, an investigational oral Factor XIa inhibitor designed to reduce the...[ Price : $8.95]
The U.S. Supreme Court declines to hear a series of pharmaceutical industry challenges to the governments Medicare drug price nego...[ Price : $8.95]
FDA faces renewed scrutiny of an internal FDA analysis of pediatric deaths reported after Covid-19 vaccination, following the rele...[ Price : $8.95]
FDA grants Bayer a priority review for its supplemental NDA for Hyrnuo (sevabertinib) as a first-line treatment for patients with ...